SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Galera Therapeutics, Inc. GRTX OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Galera Therapeutics, Inc. (GRTX) is a Biotechnology company in the Healthcare sector, currently trading at $0.08. It has a SharesGrow Score of 66/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Net income is $149M, growing at +319.7%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $7M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 11 (strong liquidity). Debt-to-assets is 0%. Total assets: $7M.

Analyst outlook: 6 / 9 analysts rate GRTX as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 55/100 (Partial), Income ?/100 (Fail).

GRTX SharesGrow Score Overview

68/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 100/100

Financials — average growth

PAST 25/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 55/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GRTX

GRTX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

GRTX: +0%/yr revenue is, +319.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

GRTX: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet GRTX: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 11 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

GRTX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

Analyst outlook: 6 / 9 analysts rate GRTX as buy (67%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range0.015-0.06

Volume6.28M

Avg Volume (30D)54.53K

Market Cap$5.95M

Beta (1Y)1.78

Share Statistics

EPS (TTM)1.51

Shares Outstanding$98.5M

IPO Date2019-11-07

Employees3

CEOJ. Mel Sorensen

Financial Highlights & Ratios

EBITDA$-6.04M

Net Income$149.05M

Operating Income$-6.04M

Total Cash$6.38M

Net Debt$-6.38M

Total Assets$7.2M

Price / Earnings (P/E)0.1

Analyst Forecast

Rating ConsensusBuy

Analysts Covering9

Buy 67% Hold 33% Sell 0%

Company Info

CountryUS

ExchangeOther OTC

CurrencyUSD

ISINUS36338D1081

Price Chart

GRTX

Galera Therapeutics, Inc. ↗ · Other OTC

Healthcare • Biotechnology

0.02 52WK RANGE 0.06

People Also View

Terns Pharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc.

Inozyme Pharma, Inc.

Acumen Pharmaceuticals, Inc.

PDS Biotechnology Corporation

Mereo BioPharma Group plc

X4 Pharmaceuticals, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message